Talimogene laherparepvec
- Generic Name
- Talimogene laherparepvec
- Brand Names
- Imlygic
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1187560-31-1
- Unique Ingredient Identifier
- 07730V90L6
- Background
Talimogene laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma. It is a genetically administered herpes simplex virus 1 (HSV-1) that expresses human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with antitumor and immune-stimulating...
- Indication
This medication is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable, cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery . Elsewhere, the EMA notes that the agent is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly ...
- Associated Conditions
- Unresectable Skin Lesion
- Associated Therapies
- -
Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma
- Conditions
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2019-10-31
- Lead Sponsor
- Amgen
- Registration Number
- NCT02297529
- Locations
- 🇨🇭
Research Site, Zürich, Switzerland
Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma
- Conditions
- Interventions
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 713
- Registration Number
- NCT02263508
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma
- Conditions
- Interventions
- First Posted Date
- 2014-08-07
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 150
- Registration Number
- NCT02211131
- Locations
- 🇨🇭
Research Site, Zürich, Switzerland
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
- Conditions
- First Posted Date
- 2014-05-28
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- Amgen
- Registration Number
- NCT02147951
- Locations
- 🇺🇸
Research Site, Wauwatosa, Wisconsin, United States
Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec
- First Posted Date
- 2013-12-18
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 61
- Registration Number
- NCT02014441
- Locations
- 🇨🇦
Research Site, Montreal, Quebec, Canada
Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 217
- Registration Number
- NCT01740297
- Locations
- 🇩🇪
Research Site, Tübingen, Germany
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
- First Posted Date
- 2006-02-09
- Last Posted Date
- 2015-12-18
- Lead Sponsor
- BioVex Limited
- Target Recruit Count
- 50
- Registration Number
- NCT00289016
- Locations
- 🇺🇸
Mountainside Hospital, Montclair, New Jersey, United States
🇬🇧Royal Marsden Hospital, London, United Kingdom
🇺🇸UCLA, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.